AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

EA FC 25 Evolutions usually require players to complete objectives, but Ultimate Team introduced a hands-off version. FC 24 introduced Evolutions, which allows ...

Your doctor will likely start you on the lowest dosage of Wegovy, which is 0.25 mg once weekly. If you do well with this treatment, they’ll likely increase your dose gradually every 4 weeks.

INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new ...

“CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo Nordisk is investigating the two molecules to determine if ...

You’ll inject Wegovy once per week. Week of therapy Wegovy weekly dose weeks 1 through 4 (the first month) 0.25 mg weeks 5 through 8 (the second month) 0.5 mg weeks 9 through 12 (the third month ...